Sugi Predict

Sugi Predict / Targets / CA12

CA12

Carbonic anhydrase 12 · O43570 · CA12 on Sugi Atlas →

884,316 patent compounds predicted against CA12, 473,606 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Benzenesulfonamide Benzenesulfonamide (SCHEMBL729) 1.00 15/20
Sulfanilamide Sulfanilamide (SCHEMBL740) 1.00 14/20
Probenecid Probenecid (SCHEMBL3663) 1.00 13/20
SCHEMBL20721 SCHEMBL20721 0.57 13/20
SCHEMBL19880 SCHEMBL19880 0.55 13/20
SCHEMBL8588 SCHEMBL8588 0.48 12/20
Coumarin Coumarin (SCHEMBL6252) 1.00 11/20
P-Toluenesulfonamide P-Toluenesulfonamide (SCHEMBL7370) 1.00 9/20
SCHEMBL19256 SCHEMBL19256 0.35 9/20
SCHEMBL19257 SCHEMBL19257 0.35 9/20
SCHEMBL6230 SCHEMBL6230 0.53 8/20
SCHEMBL7410 SCHEMBL7410 0.42 8/20
Saccharin Saccharin (SCHEMBL3816) 1.00 7/20
Saccharin Saccharin (SCHEMBL3373) 0.96 7/20
Saccharin Saccharin (SCHEMBL3374) 0.96 7/20
Biotin Biotin (SCHEMBL8763) 0.56 7/20
SCHEMBL14485 SCHEMBL14485 0.53 7/20
Esculin Esculin (SCHEMBL2893) 0.78 6/20
Esculin Esculin (SCHEMBL2894) 0.78 6/20
SCHEMBL9577 SCHEMBL9577 0.64 6/20

Clinical trials — most relevant to CA12 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer PHASE3COMPLETED
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence PHASE2/PHASE3COMPLETED
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status PHASE2RECRUITING
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies PHASE2WITHDRAWN
Immunotherapy of Cervical Cancer With V3-Cervix PHASE2UNKNOWN
Intervention of CAR-T Against Cervical Cancer PHASE1/PHASE2RECRUITING
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy PHASE2RECRUITING
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy PHASE2UNKNOWN
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) PHASE1/PHASE2ACTIVE_NOT_RECRUITING
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer PHASE2RECRUITING
Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers PHASE1COMPLETED
Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer PHASE1WITHDRAWN
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer nanCOMPLETED
The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening. nanCOMPLETED
Analysis the Positive Rate of Tumor Markers Among Physical Examination Population nanCOMPLETED
Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis nanCOMPLETED
The Etiology and Progression of Brain Tumors nanCOMPLETED
A Longitudinal Study to Analyse the Correlation Between CAI and Bilirubin nanUNKNOWN
Detection of Plasma Circulating Tumor DNA in Gastric Cancer nanUNKNOWN
Post-operative Monitoring of Gastric Cancer nanRECRUITING
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer nanCOMPLETED
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer nanCOMPLETED
Effect of CBD-Based Vaginal Suppositories on Menopausal Symptoms nanCOMPLETED
Serum Retinoic Acid Induced Protein 14 (RAI14) and Metastasis Associated Cancer Colon -1 (MACC-1) in Breast Cancer nanUNKNOWN
Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome nanUNKNOWN
Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer nanUNKNOWN
Evaluation of CEMIP in Pancreatic Cancer nanUNKNOWN
Determination of Copper and Other Trace Elements in Serum Samples From Patients With Biliary Tract Cancers nanRECRUITING
Cultured Circulating Tumor Cells in Prostate and Other Cancers nanUNKNOWN
Selecting Hypoxic Tumours for Treatment Modification nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CA12 binder may also engage these)

ProteinNameSimilarity
Q8CI85 — 0.999 Q8CI85 →
Q9MZ30 — 0.993 Q9MZ30 →
P48284 — 0.987 P48284 →
Q64444 — 0.983 Q64444 →
P28651 — 0.981 P28651 →
CA4 Carbonic anhydrase 4 0.981 landscape →
Q10462 — 0.980 Q10462 →
Q865C0 — 0.980 Q865C0 →
P08060 — 0.980 P08060 →
Q5R4U0 — 0.979 Q5R4U0 →
P61215 — 0.978 P61215 →
A0JN41 — 0.977 A0JN41 →
P18915 — 0.977 P18915 →
CA6 Carbonic anhydrase 6 0.976 landscape →
Q5R665 — 0.974 Q5R665 →
Q95323 — 0.973 Q95323 →
Q6UVY6 — 0.973 Q6UVY6 →
Q9N085 — 0.973 Q9N085 →
Q9NS85 — 0.973 Q9NS85 →
Q95203 — 0.972 Q95203 →
Q9CXI3 — 0.972 Q9CXI3 →
Q75N35 — 0.972 Q75N35 →
P35219 — 0.972 P35219 →
CA11 Carbonic anhydrase-related protein 11 0.972 landscape →
O70354 — 0.972 O70354 →
Q866X7 — 0.971 Q866X7 →
Q5PPN4 — 0.971 Q5PPN4 →
P15101 — 0.970 P15101 →
Q75N34 — 0.970 Q75N34 →
F4HUC4 — 0.970 F4HUC4 →